MX2021013427A - Metodos para tratar o prevenir el asma mediante la administracion un antagonista de il-33. - Google Patents

Metodos para tratar o prevenir el asma mediante la administracion un antagonista de il-33.

Info

Publication number
MX2021013427A
MX2021013427A MX2021013427A MX2021013427A MX2021013427A MX 2021013427 A MX2021013427 A MX 2021013427A MX 2021013427 A MX2021013427 A MX 2021013427A MX 2021013427 A MX2021013427 A MX 2021013427A MX 2021013427 A MX2021013427 A MX 2021013427A
Authority
MX
Mexico
Prior art keywords
antagonist
methods
treating
administering
preventing asthma
Prior art date
Application number
MX2021013427A
Other languages
English (en)
Spanish (es)
Inventor
Ariel Teper
Nikhil Amin
Helene Goulaouic
Andreas Jessel
Raolat Abdulai
Alex Boddy
Chih- Chi HU
Deborah Dukovic
Marcella Ruddy
Sivan Harel
Georgios Kalliolias
Original Assignee
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology filed Critical Sanofi Biotechnology
Publication of MX2021013427A publication Critical patent/MX2021013427A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
MX2021013427A 2019-05-01 2020-04-30 Metodos para tratar o prevenir el asma mediante la administracion un antagonista de il-33. MX2021013427A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962841481P 2019-05-01 2019-05-01
US201962848248P 2019-05-15 2019-05-15
US201962898900P 2019-09-11 2019-09-11
PCT/US2020/030824 WO2020223541A1 (en) 2019-05-01 2020-04-30 Methods for treating or preventing asthma by administering an il-33 antagonist

Publications (1)

Publication Number Publication Date
MX2021013427A true MX2021013427A (es) 2022-01-31

Family

ID=70802932

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013427A MX2021013427A (es) 2019-05-01 2020-04-30 Metodos para tratar o prevenir el asma mediante la administracion un antagonista de il-33.

Country Status (15)

Country Link
US (1) US20210000949A1 (enExample)
EP (1) EP3962515A1 (enExample)
JP (2) JP2022530533A (enExample)
KR (1) KR20220004708A (enExample)
CN (1) CN113766931A (enExample)
AU (1) AU2020266593B2 (enExample)
BR (1) BR112021021195A2 (enExample)
CA (1) CA3138306A1 (enExample)
CO (1) CO2021015793A2 (enExample)
IL (1) IL287275A (enExample)
MA (1) MA55807A (enExample)
MX (1) MX2021013427A (enExample)
SG (1) SG11202111255YA (enExample)
TW (1) TWI894144B (enExample)
WO (1) WO2020223541A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9574004B2 (en) 2012-08-21 2017-02-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
HUE067888T2 (hu) 2016-09-01 2024-11-28 Regeneron Pharma Módszerek az allergia megelõzésére vagy kezelésére egy IL-4R antagonista adagolásával
CA3132587A1 (en) 2019-03-21 2020-09-24 Regeneron Pharmaceuticals, Inc. Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
BR112022000740A2 (pt) 2019-07-16 2022-07-05 Sanofi Biotechnology Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r
KR20240049348A (ko) 2021-08-27 2024-04-16 메디뮨 리미티드 항-인터루킨-33 항체를 사용한 만성 폐쇄성 폐질환의 치료
CA3236201A1 (en) * 2021-11-11 2023-05-19 Regeneron Pharmaceuticals, Inc. Treatment of lung disease based upon stratification of polygenic risk score for interleukin 33 (il-33)
TW202423972A (zh) 2022-08-26 2024-06-16 英商梅迪繆思有限公司 使用抗介白素－３３抗體的氣喘治療

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
NZ609557A (en) 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
US9574004B2 (en) * 2012-08-21 2017-02-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
JO3532B1 (ar) * 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
TWI784988B (zh) * 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
MX2019012171A (es) * 2017-04-13 2019-11-25 Regeneron Pharma Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1.
EP3624820A1 (en) * 2017-04-21 2020-03-25 H. Hoffnabb-La Roche Ag Use of klk5 antagonists for treatment of a disease

Also Published As

Publication number Publication date
AU2020266593B2 (en) 2026-02-12
MA55807A (fr) 2022-03-09
KR20220004708A (ko) 2022-01-11
TW202106334A (zh) 2021-02-16
BR112021021195A2 (pt) 2022-03-03
WO2020223541A1 (en) 2020-11-05
TWI894144B (zh) 2025-08-21
IL287275A (en) 2021-12-01
SG11202111255YA (en) 2021-11-29
JP2022530533A (ja) 2022-06-29
JP2025122028A (ja) 2025-08-20
AU2020266593A1 (en) 2021-11-11
CA3138306A1 (en) 2020-11-05
EP3962515A1 (en) 2022-03-09
US20210000949A1 (en) 2021-01-07
CN113766931A (zh) 2021-12-07
CO2021015793A2 (es) 2021-11-30

Similar Documents

Publication Publication Date Title
EP4344706A3 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
MX2021013427A (es) Metodos para tratar o prevenir el asma mediante la administracion un antagonista de il-33.
AU2018253544A1 (en) Methods for treating or preventing asthma by administering an IL-4R antagonist
MX384192B (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
PH12017501934A1 (en) Methods for treating or preventing migraine headache
AU2014284235B2 (en) Methods for treating nasal polyposis by administering an IL-4R antagonist
WO2019099639A8 (en) Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
WO2018170338A3 (en) High affinity mage-a1-specific tcrs and uses thereof
AU2011332810A8 (en) Anti-IL-6 antibodies for the treatment of oral mucositis
CR20210500A (es) Anticuerpos de cadena pesada que se unen al psma
EP4353254A3 (en) Methods for treating skin infection by administering an il-4r antagonist
EP4603508A3 (en) Anti-frizzled antibodies and methods of use
MX2022007958A (es) Metodos para tratar o prevenir el asma alergica mediante la administracion de un antagonista de il-33 y/o un antagonista de il-4r.
BR112016002401A8 (pt) Métodos para reduzir as taxas de exacerbação de asma usando benralizumab
MX2020008718A (es) Anticuerpos de union a bcma y usos de los mismos.
NZ786543A (en) Compounds active towards nuclear receptors
MX2024001189A (es) Metodos para tratar la urticaria cronica espontanea por administracion de un antagonista de il-4r.
MX2024013184A (es) Metodos y composiciones para tratar apnea del sue?o
PH12021550661A1 (en) Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy
ZA201907369B (en) Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
PH12021550671A1 (en) Prodrugs of cgrp antagonists
IL289731A (en) Methods for treating or preventing asthma by administering an antagonist to il-4r
MX2022005718A (es) Anticuerpos tmem219 y usos terapeuticos de los mismos.
MX2024004762A (es) Metodos para el tratamiento del prurigo nodular mediante la administracion de un antagonista de il-4r.
MX2022003266A (es) Dosis para anticuerpos anti-triptasa.